Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- LDP to Set Up Project Team for COVID-19 Vaccine Rollout, Submits Roadmap to PM
January 20, 2021
- Kato Has High Hopes for Kono’s Knack for Inter-Ministry Coordination for Vaccinations
January 20, 2021
- AMED to Fund 17 Research Projects for Development of COVID-19 Treatments
January 20, 2021
- MHLW Eyes 1st Revision of Drug Industry Vision in 8 Years as Off-Year Re-Pricing Takes Shape: Official
January 19, 2021
- Kono Responsible for Logistics Part of COVID-19 Vaccine Rollout
January 19, 2021
- MHLW to Lift Contraindication for Combined Use of Revatio/Ancaron, but Advise “Caution”
January 19, 2021
- Kono Tapped to Oversee COVID-19 Vaccine Rollout
January 19, 2021
- PAFSC to Reexamine Seikagaku’s Osteoarthritis Med on Jan. 29, Bayer’s Larotrectinib Up for Review Too
January 18, 2021
- Administrative Penalty on Nichi-Iko Possible by March-End over Recalls
January 15, 2021
- Special Mitigation Margin for COVID-19 Up for Debate towards FY2022 Drug Price Revision: MHLW Bureau Chief
January 15, 2021
- MHLW Initiates Discussions on Amendment of Clinical Research Law
January 15, 2021
- Thaled Up for PAFSC Review for POEMS Syndrome on Jan. 27
January 15, 2021
- Chuikyo to Discuss Health Coverage for Fertility Treatments from This Summer
January 14, 2021
- Chuikyo OKs Revised NHI Pricing Rules for FY2021 Drug Re-Pricing
January 14, 2021
- MHLW to Run Fresh Survey on Drug Makers’ Responses to Promotion Guidelines
January 13, 2021
- PMDA Updates Veklury Label to Allow Its Use in Moderate COVID-19
January 8, 2021
- MHLW Compiles New Clinical Assessment Guidelines on Neuropathic Pain Drugs
January 7, 2021
- MHLW Informs of New Guideline on Exemption from Bioequivalence Studies for Oral Drugs
January 7, 2021
- Govt Eager to Roll Out 1st COVID-19 Vaccine by Late February; PM Says Pfizer’s Japan Data Ready by Month-End
January 5, 2021
- AMED to Fund 14 Projects under CiCLE Program
January 5, 2021
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…